Kirchgraber Paul R
Known title: CEO, Covance Drug DevelopmentCIK: 0001791393
Associated companies
Transaction History
| LH | ▲ Buy | Option Exercise | 4,300 | $785K | 5/19/2023 | View on chart |
| LH | ▼ Sell | Open Market | 4,300 | $933K | 5/19/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 2,886 | $648K | 3/30/2023 | View on chart |
| LH | ▲ Buy | Grant | 6,763 | $0 | 3/30/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,000 | $548K | 2/21/2023 | View on chart |
| LH | ▼ Sell | Open Market | 8,000 | $2.0M | 2/21/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 142 | $35K | 2/13/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 483 | — | 2/11/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 164 | $40K | 2/6/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 560 | — | 2/4/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 141 | $36K | 2/2/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 443 | — | 2/2/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,007 | — | 11/1/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 892 | $199K | 11/1/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,648 | $456K | 3/28/2022 | View on chart |
| LH | ▲ Buy | Grant | 3,707 | $0 | 3/27/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 108 | $29K | 2/14/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 317 | — | 2/12/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 165 | $46K | 2/4/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 560 | — | 2/4/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 443 | — | 2/2/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 144 | $39K | 2/2/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,007 | — | 11/1/2021 | View on chart |
| LH | ▼ Sell | Tax Withholding | 898 | $259K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.